Literature DB >> 19638317

Understanding CYP2D6 interactions.

Marcel J de Groot1, Florian Wakenhut, Gavin Whitlock, Ruth Hyland.   

Abstract

Owing to the polymorphic nature of CYP2D6, clinically significant issues can arise when drugs rely on that enzyme either for clearance, or metabolism to an active metabolite. Available screening methods to determine if the compound is likely to cause drug-drug interactions, or is likely to be a victim of inhibition of CYP2D6 by other compounds will be described. Computational models and examples will be given on strategies to design out the CYP2D6 liabilities for both heme-binding compounds and non-heme-binding compounds.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19638317     DOI: 10.1016/j.drudis.2009.07.005

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  8 in total

1.  Understanding the determinants of selectivity in drug metabolism through modeling of dextromethorphan oxidation by cytochrome P450.

Authors:  Julianna Oláh; Adrian J Mulholland; Jeremy N Harvey
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-28       Impact factor: 11.205

2.  Synthesis of Novel Tetrahydroisoquinoline CXCR4 Antagonists with Rigidified Side-Chains.

Authors:  Edgars Jecs; Eric J Miller; Robert J Wilson; Huy H Nguyen; Yesim A Tahirovic; Brook M Katzman; Valarie M Truax; Michelle B Kim; Katie M Kuo; Tao Wang; Chi S Sum; Mary E Cvijic; Gretchen M Schroeder; Lawrence J Wilson; Dennis C Liotta
Journal:  ACS Med Chem Lett       Date:  2017-12-20       Impact factor: 4.345

3.  Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo.

Authors:  Sun-Young Han; Chong Ock Lee; Sung-Hoon Ahn; Mi-Ok Lee; So-Young Kang; Hyuk-Jin Cha; Sung Yun Cho; Jae Du Ha; Jae Wook Ryu; Heejung Jung; Hyoung Rae Kim; Jong Sung Koh; Jongkook Lee
Journal:  Invest New Drugs       Date:  2010-11-16       Impact factor: 3.850

Review 4.  Investigating metabolite-protein interactions: an overview of available techniques.

Authors:  Grace Xiaolu Yang; Xiyan Li; Michael Snyder
Journal:  Methods       Date:  2012-06-28       Impact factor: 3.608

Review 5.  Studies of metabolite-protein interactions: a review.

Authors:  Ryan Matsuda; Cong Bi; Jeanethe Anguizola; Matthew Sobansky; Elliott Rodriguez; John Vargas Badilla; Xiwei Zheng; Benjamin Hage; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2013-11-25       Impact factor: 3.205

6.  Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population.

Authors:  Q Xu; X Wu; M Li; H Huang; C Minica; Z Yi; G Wang; L Shen; Q Xing; Y Shi; L He; S Qin
Journal:  Pharmacogenomics J       Date:  2015-08-18       Impact factor: 3.550

Review 7.  Modeling of interactions between xenobiotics and cytochrome P450 (CYP) enzymes.

Authors:  Hannu Raunio; Mira Kuusisto; Risto O Juvonen; Olli T Pentikäinen
Journal:  Front Pharmacol       Date:  2015-06-12       Impact factor: 5.810

8.  CYP2D6-inhibiting drugs and risk of fall injuries after newly initiated antidepressant and antipsychotic therapy in a Swedish, register-based case-crossover study.

Authors:  Marja-Liisa Dahl; Karin Leander; Max Vikström; Clara Frumerie; Sofia Nordenmalm; Jette Möller; Karin Söderberg-Löfdal
Journal:  Sci Rep       Date:  2021-03-11       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.